Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy
Authors:
- 1 November 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 1 (5) , 309-319
Abstract
Although antitumor activity of herpes simplex virus 1 (HSV-1) ICP0 null oncolytic vectors has been validated in murine breast cancer models, oncolytic virus treatment alone is insufficient to break immune tolerance. Thus, we investigated enhancing efficacy through combination therapy with the immunogenic cell death–inducing chemotherapeutic drug, mitoxantrone. Despite a lack of enhanced cytotoxicity in vitro, HSV-1 ICP0 null oncolytic virus KM100 with 5 μmol/L mitoxantrone provided significant survival benefit to BALB/c mice bearing Her2/neu TUBO-derived tumors. This protection was mediated by increased intratumoral infiltration of neutrophils and tumor antigen-specific CD8+ T cells. Depletion studies verified that CD8-, CD4-, and Ly6G-expressing cells are essential for enhanced efficacy of the combination therapy. Moreover, the addition of mitoxantrone to KM100 oncolytic virus treatment broke immune tolerance in BALB-neuT mice bearing TUBO-derived tumors. This study suggests that oncolytic viruses in combination with immunogenic cell death–inducing chemotherapeutics enhance the immunogenicity of the tumor-associated antigens, breaking immunologic tolerance established toward these antigens. Cancer Immunol Res; 1(5); 309–19. ©2013 AACR.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- Oncolytic viruses: a step into cancer immunotherapyVirus Adaptation and Treatment, 2011
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses CollideMolecular Therapy, 2011
- Targeting Tumor Vasculature With an Oncolytic VirusMolecular Therapy, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic VirotherapyMolecular Therapy, 2011
- Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase InhibitorsPLOS ONE, 2010
- Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic DeathCancer Research, 2010
- A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus SensitizersMolecular Therapy, 2010
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends in Immunology, 2010
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences, 2006